000			01809 a2200493 4500
005			20250512080527.0
264		0	_c19850328
008			198503s 0 0 eng d
022			_a0032-1052
024	7		_a10.1097/00006534-198503000-00027 _2doi
040			_aNLM _beng _cNLM
100	1		_aGargan, T J
245	0	0	_aBreast cancer chemotherapy: perioperative considerations in breast reconstruction. _h[electronic resource]
260			_bPlastic and reconstructive surgery _cMar 1985
300			_a430-4 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Review
650	0	4	_aAdult
650	0	4	_aAlkylating Agents _xadverse effects
650	0	4	_aAntimetabolites, Antineoplastic _xadverse effects
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aBreast _xsurgery
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aClinical Trials as Topic
650	0	4	_aCombined Modality Therapy
650	0	4	_aCyclophosphamide _xtherapeutic use
650	0	4	_aDoxorubicin _xadverse effects
650	0	4	_aFemale
650	0	4	_aFluorouracil _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aMastectomy
650	0	4	_aMelphalan _xtherapeutic use
650	0	4	_aMethotrexate _xtherapeutic use
650	0	4	_aMiddle Aged
650	0	4	_aPrednisone _xadverse effects
650	0	4	_aSurgery, Plastic
650	0	4	_aTamoxifen _xadverse effects
650	0	4	_aThiotepa _xtherapeutic use
650	0	4	_aVincristine _xadverse effects
700	1		_aCome, S E
700	1		_aSatwicz, P R
773	0		_tPlastic and reconstructive surgery _gvol. 75 _gno. 3 _gp. 430-4
856	4	0	_uhttps://doi.org/10.1097/00006534-198503000-00027 _zAvailable from publisher's website
999			_c3925097 _d3925097